Neurochemical Research Intros Eye Specific Treatment for Macular Degeneration Sufferers
SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--Nov. 21, 2001--Neurochemical Research Corp. (Pink Sheets:NCRH), a marketer of condition-specific dietary supplements, has announced a compelling product introduction, VisionKare(TM), developed specifically for macular degeneration sufferers and recently validated by a National Eye Institute (NEI) Study conducted by the National Institutes of Health.
The study found that high levels of antioxidants and zinc found in the VisionKare product significantly reduce the risk of advanced age-related macular degeneration (AMD) and its associated vision loss.
Company president Carol Slavin said, "Neurochemical Research decreased the dosage of nutrients utilized in the study because older people who suffer from this disorder take a considerable number of medications and high-dose nutrients can interfere with their other medications. We formulated a similar, but more complex product utilizing the recommended antioxidants and zinc plus other highly specific eye nutrients which will help preserve the sight of the more than 13 million people over the age of 65 who have macular degeneration."
Paul A. Sieving, M.D., Ph.D, director of National Eye Institute said, "This is an exciting discovery because, for people at high risk for developing advanced AMD, these nutrients are the first effective treatment to slow the progression of the disease." |
